Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Charles River Laboratories Intl (CRL)

Charles River Laboratories Intl (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,786,706
  • Shares Outstanding, K 49,228
  • Annual Sales, $ 4,015 M
  • Annual Income, $ -144,340 K
  • EBIT $ 580 M
  • EBITDA $ 1,149 M
  • 60-Month Beta 1.63
  • Price/Sales 2.19
  • Price/Cash Flow 8.13
  • Price/Book 2.77

Options Overview Details

View History
  • Implied Volatility 46.71% (+0.39%)
  • Historical Volatility 51.81%
  • IV Percentile 65%
  • IV Rank 26.76%
  • IV High 86.39% on 04/11/25
  • IV Low 32.21% on 06/18/25
  • Expected Move (DTE 18) 13.86 (7.76%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 711
  • Volume Avg (30-Day) 2,090
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 15,472
  • Open Int (30-Day) 11,112
  • Expected Range 164.76 to 192.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.05
  • Number of Estimates 8
  • High Estimate 2.43
  • Low Estimate 1.91
  • Prior Year 2.34
  • Growth Rate Est. (year over year) -12.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.33 +22.06%
on 02/18/26
218.69 -18.33%
on 02/03/26
-34.61 (-16.23%)
since 02/02/26
3-Month
146.33 +22.06%
on 02/18/26
228.88 -21.96%
on 01/13/26
+3.85 (+2.20%)
since 12/02/25
52-Week
91.86 +94.44%
on 04/11/25
228.88 -21.96%
on 01/13/26
+13.30 (+8.05%)
since 02/28/25

Most Recent Stories

More News
Charles River Laboratories to Present at TD Cowen and Barclays Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including: TD Cowen 46 th...

CRL : 178.61 (+0.07%)
Charles River Laboratories Provides Update on Planned Divestitures

– Announces Signing of Definitive Agreements to Divest the CDMO and Cell Solutions Businesses and Certain European Discovery Services Assets – – Updates 2026 Financial...

CRL : 178.61 (+0.07%)
Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know

Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know

ENOV : 25.70 (+0.90%)
IART : 10.43 (-8.35%)
BTSG : 41.58 (+0.36%)
CRL : 178.61 (+0.07%)
IQV : 174.27 (-2.54%)
What Are Wall Street Analysts' Target Price for Charles River Laboratories Stock?

Charles River Laboratories has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

XLV : 158.53 (-1.04%)
$SPX : 6,881.62 (+0.04%)
CRL : 178.61 (+0.07%)
CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers

CRL Q4 Deep Dive: Flat Sales and Margin Pressures as Biotech Demand Recovers

CRL : 178.61 (+0.07%)
Stocks Rally on Signs of US Economic Resilience

The S&P 500 Index ($SPX ) (SPY ) today is up +0.84%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.20%. March E-mini S&P futures (ESH26...

AMAT : 372.18 (-0.03%)
B : 50.55 (-0.37%)
KNF : 88.78 (-0.22%)
HL : 24.63 (-1.12%)
GPN : 77.89 (+1.87%)
CDE : 26.94 (-0.77%)
ADI : 352.41 (-0.95%)
GLBE : 34.63 (-0.97%)
$IUXX : 24,992.60 (+0.13%)
ASML : 1,423.54 (-1.86%)
ZNM26 : 113-055 (+0.08%)
ESH26 : 6,872.00 (-0.24%)
Stocks Climb on Solid US Economic News and Easing AI Jitters

The S&P 500 Index ($SPX ) (SPY ) today is up +0.36%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.47%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.40%. March E-mini S&P futures (ESH26...

B : 50.55 (-0.37%)
KNF : 88.78 (-0.22%)
HL : 24.63 (-1.12%)
GPN : 77.89 (+1.87%)
CDE : 26.94 (-0.77%)
ADI : 352.41 (-0.95%)
DDOG : 111.11 (-0.76%)
GLBE : 34.63 (-0.97%)
$IUXX : 24,992.60 (+0.13%)
FIGR : 29.72 (+17.56%)
ZNM26 : 113-055 (+0.08%)
ESH26 : 6,872.00 (-0.24%)
Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations

Charles River Laboratories (NYSE:CRL) Beats Q4 CY2025 Sales Expectations

CRL : 178.61 (+0.07%)
Charles River: Q4 Earnings Snapshot

Charles River: Q4 Earnings Snapshot

CRL : 178.61 (+0.07%)
Charles River Laboratories Announces Executive Appointments

Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles...

CRL : 178.61 (+0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research...

See More

Key Turning Points

3rd Resistance Point 186.78
2nd Resistance Point 182.99
1st Resistance Point 180.80
Last Price 178.61
1st Support Level 174.82
2nd Support Level 171.03
3rd Support Level 168.84

See More

52-Week High 228.88
Last Price 178.61
Fibonacci 61.8% 176.54
Fibonacci 50% 160.37
Fibonacci 38.2% 144.20
52-Week Low 91.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar